Xeris Biopharma Holdings, Inc. $XERS Stake Boosted by Deutsche Bank AG

Deutsche Bank AG boosted its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 492.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 756,407 shares of the company's stock after purchasing an additional 628,807 shares during the quarter. Deutsche Bank AG owned approximately 0.48% of Xeris Biopharma worth $4,153,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. R Squared Ltd boosted its holdings in Xeris Biopharma by 27.7% in the first quarter. R Squared Ltd now owns 15,730 shares of the company's stock worth $86,000 after purchasing an additional 3,410 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Xeris Biopharma by 4.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company's stock worth $273,000 after purchasing an additional 3,447 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Xeris Biopharma by 31.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company's stock worth $55,000 after purchasing an additional 3,847 shares during the period. Apollon Wealth Management LLC lifted its stake in Xeris Biopharma by 19.8% in the first quarter. Apollon Wealth Management LLC now owns 24,160 shares of the company's stock valued at $133,000 after buying an additional 4,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Xeris Biopharma by 5.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 170,482 shares of the company's stock valued at $578,000 after acquiring an additional 9,506 shares during the period. Institutional investors and hedge funds own 42.75% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on XERS shares. Wall Street Zen raised shares of Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. Oppenheimer boosted their price target on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th. HC Wainwright started coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They set a "buy" rating and a $10.00 price target for the company. Finally, Leerink Partners boosted their price target on shares of Xeris Biopharma from $7.00 to $9.00 and gave the company an "outperform" rating in a report on Tuesday. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $7.08.

Insiders Place Their Bets

In other Xeris Biopharma news, Director Dawn Halkuff sold 42,500 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $7.28, for a total value of $309,400.00. Following the sale, the director directly owned 115,000 shares in the company, valued at approximately $837,200. The trade was a 26.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kevin Mcculloch purchased 25,000 shares of the company's stock in a transaction on Friday, June 13th. The stock was acquired at an average price of $4.38 per share, for a total transaction of $109,500.00. Following the completion of the transaction, the insider owned 1,708,585 shares of the company's stock, valued at $7,483,602.30. This represents a 1.48% increase in their position. The disclosure for this purchase can be found here. 6.47% of the stock is owned by company insiders.

Xeris Biopharma Price Performance

Shares of NASDAQ XERS traded up $0.0950 during midday trading on Friday, reaching $7.6850. 466,846 shares of the company traded hands, compared to its average volume of 2,547,979. Xeris Biopharma Holdings, Inc. has a 52 week low of $2.48 and a 52 week high of $7.79. The stock has a 50-day moving average price of $5.47 and a 200 day moving average price of $4.82. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -36.74 and a beta of 0.65.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to the consensus estimate of $64.58 million. As a group, analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.